Granted Patent
B2
US 11,583,593 · App. 16/654,194 · Granted Feb 21, 2023
Antibody-ALK5 inhibitor conjugates and their uses
Assignee:
Synthis Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses.
Claims (3)
1. A composition comprising an ALK5 inhibitor covalently attached to a protease-sensitive linker, wherein the wherein the ALK5 inhibitor has the structure
2. The composition of claim 1 , wherein the protease-sensitive linker comprises a dipeptide, a tripeptide, a tetrapeptide, or a pentapeptide.
3. The composition of claim 1 , wherein the protease-sensitive linker comprises a valine-citrulline dipeptide.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 14, 2020
From: THOMAS-KARYAT, DORI A.
To: SYNTHIS, LLC
Reel/Frame 054639/0608 →
MERGER AND CHANGE OF NAME
Recorded Dec 14, 2020
From: SYNTHIS THERAPEUTICS, INC.; SYNT, INC.
To: SYNTHIS THERAPEUTICS, INC.
Reel/Frame 054640/0293 →
CHANGE OF NAME
Recorded Dec 14, 2020
From: SYNTHIS, LLC
To: SYNTHIS THERAPEUTICS, INC.
Reel/Frame 054749/0379 →
Continuity (5)
Continuation
16286122
· Feb 26, 2019
Continuation
16029351
· Jul 6, 2018
Continuation
15404233
· Jan 12, 2017
Provisional Application
62278928
· Jan 14, 2016
Cited By (1)